null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed via venture rounds; low leverage ratio (<0.1x debt/equity estimated)

Negligible direct interest rate exposure; cash runway sensitivity moderate as higher rates increase cost of future equity/debt raises

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API (active pharmaceutical ingredient) sourcing from China/India CMOs; geopolitical chokepoints are Sino-US trade tensions and Indian export controls

Pre-commercial US-focused company; no meaningful international revenue markets yet; currency devaluation exposure effectively null

Predominantly US-based operations; clinical trials may have ex-US sites but no revenue-generating international presence currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or few contract research organizations (CROs) and CMOs; likely >30% operational input from top vendor given early-stage scale

Clinical-stage biopharmaceutical; revenue model is future drug sales/licensing, not cloud-native; cloud termination would disrupt operations but not core IP

Potential licensing/partnership revenue secondary model; cloud disruption would affect data management but pipeline IP resides in patents and wet-lab data

Moderate API coupling risk; CRO switching costs are high (12-18 months transition); cloud platform switching feasible but disruptive to trial data workflows

Low Howey risk; revenue model is drug commercialization/licensing, not investment contract; equity is standard VC-backed biotech structure

Very High

Moderate GDPR/CCPA exposure from clinical trial patient data; must comply with 21 CFR Part 11 and EU clinical trial regulations; active compliance burden

Low antitrust risk currently; pre-commercial stage with no market dominance; future orphan/niche dermatology focus limits market concentration concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently 0% recurring revenue; pre-commercial stage; future model will be transactional drug sales plus potential milestone-based licensing deals

Primary monetization via proprietary drug approvals (EVM1, EVM2 pipeline) targeting atopic dermatitis/prurigo nodularis; licensing partnerships secondary

Pricing architecture not yet established; comparable biologics in derm (dupilumab ~$35K/year) suggest premium specialty pricing; payer negotiation risk high

Moderate-to-high potential pricing power if differentiated mechanism confirmed; dependent on clinical superiority data vs. existing IL-31/IL-4 pathway drugs

Targeted gross margin 75-85% at commercial scale, typical for specialty biologics; near-term margins negative as R&D spend dominates

No free-rider leakage problem applicable; prescription drug model with payer/patient controls; patient adherence and insurance coverage are primary retention risks

Revenue growth sublinear to headcount at commercialization; small commercial team can scale via CRO/CMO outsourcing; R&D headcount relatively fixed per program

Marginal cost of growth driven by manufacturing scale-up and clinical trial costs, not headcount; biotech model is capital-intensive but operationally leverageable

Not applicable; Evommune is not a franchise business model

At 10x scale, CAC economics depend on specialty pharma sales force efficiency; dermatologist call patterns suggest high CAC but strong LTV for chronic disease

No meaningful network effects; drug efficacy is independent of user base size; physician adoption driven by clinical data, not network dynamics

-30.6% Return on Assets (Negative equity)

Moderate recession resistance; atopic dermatitis/prurigo nodularis are chronic, debilitating conditions but specialty drug affordability sensitive to insurance coverage cuts

Dermatologists and allergists prescribing for moderate-to-severe atopic dermatitis and prurigo nodularis patients; concentrated specialty prescriber base

Payers (insurers, PBMs) and patients with chronic pruritic conditions; high concentration risk if top 3 PBMs restrict formulary access

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.8% CapEx / Revenue (Low-CapEx Asset-Light)

0002044725

EVMN